Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.49 |
| ▸ | NAAA | Q02083 | 3/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | HPD | P32754 | 1/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.44 |
| ▸ | GCK | P35557 | 1/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL862827 | 0.88 | NR4A1 (0.57) | MEN1KMT2ANR4A2NAAAMAOB | |
| SCHEMBL21805840 | 0.81 | TSHR (0.40) | KMT2ANAAAALDH1A1SRD5A2LMNA | |
| SCHEMBL5551769 | 0.78 | LMNA (0.42) | MEN1KMT2ANR4A2NAAAMAOB | |
| SCHEMBL13404895 | 0.78 | MGLL (0.37) | MEN1KMT2AALDH1A1LMNAHPGD | |
| SCHEMBL6851170 | 0.77 | KMT2A (0.68) | MEN1KMT2ANR4A2MAOBNR4A1 | |
| SCHEMBL21110476 | 0.77 | KMT2A (0.42) | MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL19309377 | 0.76 | KMT2A (0.53) | KMT2AALDH1A1LMNA | |
| SCHEMBL133554 | 0.76 | KMT2A (0.53) | KMT2AALDH1A1LMNA | |
| SCHEMBL10041303 | 0.76 | LMNA (0.47) | MEN1KMT2AALDH1A1SRD5A2LMNA | |
| SCHEMBL183994 | 0.76 | LMNA (0.70) | MEN1KMT2ANR4A2MAOBNR4A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143366-B2 | Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same | BIOCON LIMITED (IN) | 2012-03-27 | — | — | US | disclosed |
| US-8143366-B2 | Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same | BIOCON LIMITED (IN) | 2012-03-27 | — | — | US | disclosed |
| US-20100081782-A1 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | EKWURIBE NNOCHIRI N | 2010-04-01 | — | — | US | disclosed |
| US-20100081782-A1 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | EKWURIBE NNOCHIRI N | 2010-04-01 | — | — | US | disclosed |
| US-7625995-B2 | Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same | BIOCON LIMITED (IN) | 2009-12-01 | — | — | US | disclosed |
| US-7625995-B2 | Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same | BIOCON LIMITED (IN) | 2009-12-01 | — | — | US | disclosed |
| US-20080146778-A1 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | BIOCON LIMITED (IN) | 2008-06-19 | — | — | US | disclosed |
| US-20080146778-A1 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | BIOCON LIMITED (IN) | 2008-06-19 | — | — | US | disclosed |
| US-7335751-B2 | Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same | BIOCON LIMITED (IN) | 2008-02-26 | — | — | US | disclosed |
| US-7335751-B2 | Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same | BIOCON LIMITED (IN) | 2008-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146778-A1 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | ALK, AOX1, OGFR | MEN1 4097/4885KMT2A 1543/4885NR4A2 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.